Ennovabio, a Shanghai novel drug company, raised $10 million in a pre-A funding, led by HighLight Capital. Ennovabio is developing an innovative drug that targets brain glioma, while it also builds a compound library that will be used to make deals with other pharmas. The company was founded in December 2016 by Jiang Lei, who worked previously with Switzerland’s Novartis and then Shanghai HaiHe Pharma and Shanghai Green Valley Pharma.
